In a patient with glomerular hematuria, proteinuria and impaired renal function, how can I differentiate autoimmune glomerulonephritis from lupus nephritis and IgA nephropathy?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: March 5, 2026 • View editorial policy

Personalize

Help us tailor your experience

Which best describes you? Your choice helps us use language that's most understandable for you.

Differentiating Autoimmune Glomerulonephritis from Lupus Nephritis and IgA Nephropathy

The definitive differentiation requires kidney biopsy with immunofluorescence microscopy and serologic testing, as these three entities have distinct immunofluorescence patterns and serologic profiles that cannot be reliably distinguished by clinical presentation alone. 1

Initial Diagnostic Approach

Serologic Testing (Obtain Before Biopsy)

  • ANCA testing (MPO and PR3): Positive in 80-90% of pauci-immune glomerulonephritis cases 1
  • ANA, anti-dsDNA, complement levels (C3, C4): Essential for lupus nephritis diagnosis 1
  • Anti-GBM antibodies: To exclude anti-GBM disease 1
  • Serum IgA levels: May be elevated in IgA nephropathy but not diagnostic 2

Clinical Clues (But Not Diagnostic)

  • IgA nephropathy: Episodic visible hematuria concurrent with upper respiratory infections (synpharyngitic hematuria) occurs in up to 30% of cases; mean age 34-45 years 2
  • Lupus nephritis: Requires meeting ACR criteria for SLE with persistent proteinuria >0.5 g/day and/or active urinary sediment 1
  • ANCA-associated GN: Often presents with rapidly progressive renal failure and may have extrarenal vasculitis manifestations 1

Kidney Biopsy: The Gold Standard

All patients with clinical evidence of active glomerulonephritis should undergo kidney biopsy unless strongly contraindicated. 1

Immunofluorescence Patterns (Pathognomonic)

  • IgA nephropathy: Mesangial dominant or co-dominant IgA deposits 1, 2
  • Lupus nephritis: "Full-house" pattern with multiple immunoglobulin classes (IgG, IgA, IgM) plus C3 and often C1q in mesangial and/or capillary walls 1
  • Pauci-immune GN (ANCA-associated): Negative or minimal (<1-2+) immunoglobulin deposits; may have fibrinogen in areas of necrosis 1

Light Microscopy Patterns

  • IgA nephropathy: Variable patterns including mesangial proliferative, crescentic, or endocapillary proliferation; use MEST-C score for classification 3
  • Lupus nephritis: Classified by ISN/RPS criteria (Classes I-VI); Class III/IV show subendothelial deposits and proliferative changes 1
  • ANCA GN: Necrotizing and crescentic pattern with fibrinoid necrosis and glomerular basement membrane rupture 1

Electron Microscopy Findings

  • IgA nephropathy: Mesangial electron-dense deposits 1
  • Lupus nephritis: Subendothelial, mesangial, and/or subepithelial deposits depending on class 1
  • ANCA GN: Absence of electron-dense deposits (pauci-immune) 1

Critical Diagnostic Pitfalls

Overlapping Conditions

  • ANCA-positive lupus nephritis: Approximately 25% of anti-GBM GN patients also have circulating ANCA; fibrinoid necrosis in lupus biopsy should prompt ANCA testing 1
  • IgA nephropathy with lupus: Rare coexistence; lupus with IgA deposits may follow a more indolent course than typical lupus nephritis but can still progress 4
  • Idiopathic full-house nephropathy: Full-house immunofluorescence pattern without meeting SLE criteria; these patients have poor renal outcomes and 20% may develop SLE later 5

Segmental IgM and C3 Staining

  • Segmental staining for IgM, C3, and occasionally C1q is common in areas of segmental sclerosis and should not be interpreted as immune-complex deposition 1

Algorithmic Approach

  1. Obtain serologies immediately: ANCA, ANA, anti-dsDNA, complement, anti-GBM antibodies 1
  2. Perform kidney biopsy with adequate tissue for light microscopy, immunofluorescence, and electron microscopy 1
  3. Immunofluorescence pattern determines pathogenic type:
    • Dominant IgA = IgA nephropathy 1
    • Full-house (multiple Ig + complement) = Lupus nephritis 1
    • Negative/minimal Ig = Pauci-immune GN (check ANCA) 1
  4. Correlate biopsy with serology: ANCA positivity confirms ANCA GN; SLE criteria confirm lupus nephritis 1
  5. If discordant findings, consider overlap syndromes or secondary causes 1, 4

When to Treat Before Biopsy

If clinical presentation is compatible with rapidly progressive glomerulonephritis and ANCA or anti-GBM antibodies are positive, do not delay immunosuppressive therapy while awaiting biopsy, but perform biopsy as soon as feasible after treatment initiation. 1 The same applies if lupus nephritis is strongly suspected with positive lupus serologies and rapidly declining renal function. 1 However, infection must be excluded with maximal certainty before initiating significant immunosuppression. 1

References

1
Guideline

Guideline Directed Topic Overview

Dr.Oracle Medical Advisory Board & Editors, 2025

3
Research

[Diagnosis and Treatment of IgA Nephropathy-2023].

Wiener klinische Wochenschrift, 2023

4
Research

Lupus and IgA nephropathy: coexistence or coincident?

Wiener klinische Wochenschrift, 2025

Related Questions

In a patient with glomerular hematuria, proteinuria, and declining estimated glomerular filtration rate, how do lupus nephritis, IgA nephropathy, and ANCA‑associated pauci‑immune glomerulonephritis differ in their pathophysiology?
What is the appropriate diagnostic work‑up and initial treatment for a patient with suspected autoimmune glomerulonephritis?
What is the appropriate management for a 7-year-old male with mixed nephrotic‑nephritic syndrome secondary to confirmed IgA nephropathy presenting with oliguria, hematuria, and generalized edema?
What is the next step in management of a 45-year-old man with IgA nephropathy on maximally tolerated Farxiga (dapagliflozin), Mounjaro (tirzepatide) and telmisartan presenting with impaired renal function and significant proteinuria?
What is the initial treatment approach for acute glomerulonephritis?
What is the appropriate evaluation and treatment for a patient with serum iron 27 µg/dL, transferrin 327 mg/dL, and transferrin saturation 6%?
What metabolic etiologies could account for the rapid deterioration of a 35‑year‑old hypertensive man with fever, cough, bilateral lung consolidations, neutrophilic leukocytosis, elevated C‑reactive protein (CRP), anemia, and severe acute kidney injury (AKI) with markedly elevated blood urea nitrogen (BUN) and creatinine?
What is the appropriate evaluation and management for a patient with an elevated CK‑MB (creatine kinase‑MB)?
In a female patient with left lower quadrant abdominal pain, tenderness on right lower quadrant palpation, constipation, and decreased appetite, what is the appropriate initial assessment, differential diagnosis, and management plan?
What are the criteria and steps to determine kidney transplant compatibility, including ABO blood type matching, HLA typing, cross‑match results, panel‑reactive antibody levels, and management of donor‑specific antibodies?
Is vitamin C effective for treating fever, and what dosage is safe?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

Ask Question